AAIC 2025 Abstract·23 DecComplement meets Tau: Exploring the effects of a novel C3‐targeting siRNA in a Tauopathy mouse modelExperiments in animalsInterventionsPaper
AAIC 2025 Abstract·23 DecComplement‐mediated vascular inflammation contributes to anti‐amyloid mAb‐induced ARIA in miceExperiments in animalsInterventionsPaper
AAIC 2025 Abstract·23 DecMouse models for studying anti‐amyloid antibody‐induced ARIAReviewMechanismsPaper
AAIC 2025 Abstract·23 DecInvestigating the Effects of C1q‐Blocking Using a CDC‐Mutant 3D6 Antibody on ARIA in 5XE4 MiceExperiments in animalsInterventionsPaper
AAIC 2025 Abstract·23 DecImpact of C3 Lowering at Early and Late Stages of Tau Pathology in PS19 MiceExperiments in animalsMechanismsPaper
AAIC 2025 Abstract·23 DecDifferential Vascular and Non‐Vascular Binding Patterns of ACU193 and R‐Lecanemab in APP;hAPOE4 Mouse Brain SectionsExperiments in animalsMechanismsPaper
AAIC 2025 Abstract·23 DecLecanemab, aducanumab, and donanemab bind the same human Alzheimer disease Aβ aggregates at different epitopesStudy in peopleMechanismsPaper